News
CTC counts signal treatment choice in ER-positive/HER2-negative metastatic breast cancer
SAN ANTONIO – Circulating tumor cell counts rival clinician choice for determining whether to prescribe hormonal therapy or chemotherapy,...
News
Combo bests standard care in younger CLL patients
SAN DIEGO—In a phase 3 trial, ibrutinib plus rituximab (IR) improved survival when compared with standard chemoimmunotherapy in patients younger...
News
DTCs in marrow herald worse outcomes for early breast cancer
SAN ANTONIO – Disseminated tumor cells detected in marrow at diagnosis or primary surgery for early breast cancer are associated with worse...
News
Ibrutinib-rituximab ‘new standard of care’ in younger CLL patients
SAN DIEGO – Survival and safety outcomes were better with ibrutinib and rituximab than with the FCR regimen.
News
Tamoxifen at 5 mg halves recurrence of breast intraepithelial neoplasia
SAN ANTONIO – For patients with ADH, DCIS, or LCIS, one-fourth of the standard dose reduced risk for both invasive disease/DCIS and contralateral...
News
Mutation confers resistance to venetoclax in CLL
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients...
Video
CTC matches MD judgment for mBC therapeutic choice
SAN ANTONIO – For patients with ER-positive, HER2-negative metastatic breast cancer, the use of CTC counts can help clinicians decide between...
News
Low-dose tamoxifen halves recurrence of breast intraepithelial neoplasia
SAN ANTONIO – Women with breast intraepithelial neoplasms who took tamoxifen for 3 years at a dose of 5 mg per day had a 50% reduction in risk of...
News
Adjuvant T-DM1 halves HER2-positive invasive breast cancer recurrence
SAN ANTONIO – The 3-year invasive disease-free recurrence was 88.3% for patients with residual disease treated with T-DM1 versus 77.0% with...
News
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
Video
KATHERINE: T-DM1 doubles HER2-positive invasive disease-free survival
SAN ANTONIO – For the primary endpoint of invasive disease-free survival, T-DM1 was associated with a hazard ratio of 0.50.
News
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remission
SAN DIEGO – Minimal residual disease and mutational clearance were seen in a significant proportion of patients.
News
Shorter R-CHOP regimen noninferior in certain DLBCL patients
SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy...
News
Update shows durable responses in rel/ref DLBCL
SAN DIEGO—An updated analysis of the JULIET trial showed that tisagenlecleucel produced a high rate of durable responses in adults with relapsed...
Video
JULIET: CAR T cells go the distance in r/r DLBCL
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.